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Introduction and epidemiology
Group recommendations
• More than 20% of patients are expected to have acute 
cardiovascular dysfunction in the perioperative period 
of cardiac surgery
• Classiﬁ cation of acute heart failure by European 
Society of Cardiology/American College of Cardiology 
Foun dation/American Heart Association is not appli-
cable to the perioperative period of cardiac surgery
Acute heart failure (HF) is deﬁ ned as a rapid onset of 
symptoms secondary to abnormal cardiac function 
result ing in an inability to pump suﬃ  cient blood at 
normal end-diastolic pressures. Acute HF presents 
clinically as cardiogenic shock, pulmonary oedema, or 
left/right/biventricular congestive HF, sometimes in 
conjunction with high blood pressure (hyper tensive HF) 
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or high cardiac output (CO) [1]. Epidemiological studies 
have revealed the high morbidity and mortality of 
hospitalised acute HF patients [2-4], and the European 
Heart Failure Survey II (EHFS II) [5] and the EFICA study 
(Epidémiologie Francaise de l’Insuﬃ  sance Cardiaque 
Aiguë) [6] have provided insights into the epidemiology of 
those admitted to ICUs. Diﬀ erentiating between these 
scenarios perioperatively might be more complex than in 
non-cardiosurgical settings [7-9], as typical symptoms are 
often missing, while measured physiologic para meters are 
inﬂ u enced by treatment. Additionally, fre quently occur-
ring cardiac stunning - a transient, rever sible, post-
operative contrac tility impairment - may require inotropic 
support to prevent tissue hypoperfusion and organ 
dysfunction.
In a recent prospective survey, the presentation and 
epi demio logy of acute HF were compared in a medical 
and a cardio surgical ICU [10]. Th e clinical course varied 
con siderably in the three speciﬁ ed patient subgroups 
(medical, elective and emergency cardiosurgical patients), 
with out come mostly inﬂ uenced by co-morbidities, organ 
dysfunction, and surgical treatment options. Th e 
distinction between cardiogenic shock and transient 
postoperative cardiac stunning - diagnosed in 45% of 
elective patients - is impor tant as they are associated with 
diﬀ erent hospital paths and outcomes (Figure 1). Patients 
with only postoperative stun ning can usually be rapidly 
weaned oﬀ  inotropic support.
In another study, postcardiotomy cardiogenic shock 
occurred in only 2% to 6% of all adult cardiosurgical 
procedures, albeit associated with high mortality rates 
[11]. Twenty-ﬁ ve percent of patients undergoing elective 
coronary artery bypass graft (CABG) surgery require 
inotropic support for postoperative myocardial dys-
function [12]. Transesophageal echocardio graphy (TEE) 
shows that right ventricular (RV) dysfunction is present 
in about 40% of postoperative patients who develop 
shock [13]. Postoperative cardiovascular dysfunction may 
also be characterised by unexpectedly low systemic 
vascular resistance (SVR), that is, vasodilatory shock. 
Th ese ﬁ ndings could help in the evaluation of therapeutic 
options [14,15].
Risk stratifi cation
Group recommendations
• Indicators of major clinical risk in the perioperative 
period are: unstable coronary syndromes, decom-
pensated HF, signiﬁ cant arrhythmias and severe 
valvular disease
• Clinical risk factors include history of heart disease, 
compensated HF, cerebrovascular disease, presence of 
diabetes mellitus, renal insuﬃ  ciency and high-risk 
surgery
• the EuroSCORE predicts perioperative cardiovascular 
alteration in cardiac surgery well, although in those 
older than 80 years it overestimates mortality
• B-type natriuretic peptide level before surgery is an 
additional risk stratiﬁ cation factor
Risk stratiﬁ cation is increasingly used in open-heart 
surgery to help adjust available resources to predicted 
outcome. Th e latter is mostly calculated by the 
EuroSCORE (European System for Cardiac Operative 
Risk Evaluation; Table 1) [16].
As the simple EuroSCORE sometimes underestimates 
risk when certain combinations of risk factors co-exist, a 
more complete logistical version has been developed, 
resulting in more accurate risk prediction for particularly 
high risk patients. Figure 2 depicts the predicted factors 
of post operative low CO syndrome (abscissa) versus the 
logit score (ordinate) for several combinations of 
covariate risk factors for low CO syndrome [17].
Table  2 lists other scoring systems besides the 
EuroSCORE used to assess risk in cardiac surgery. 
Essentially, according to all risk indices HF constitutes a 
high risk, and a left ventricular ejection fraction ≤35% 
could be an indicator of adverse outcome [18]. Compared 
to other risk factors, HF is espe cially related to poor long-
term outcome. Preoperative assess ment opens up a ‘golden 
hour’ for identiﬁ cation and initiation of thera peutic 
interventions in patients with myo cardial viability, such as 
coronary revascularization, cardiac re synchro nization, and 
medical therapy. Due to thera peutic advances, the 
EuroSCORE slightly overestimates the peri operative risk, 
which is why a project to update the sensitivity of the 
EuroSCORE is currently being considered [19-24].
Figure 1. Kaplan Meier curves showing survival rates of ICU 
patients with diff erent acute heart failure (HF) syndromes over 
time, starting at the day of ICU admission. The small vertical lines 
indicate the time points when patients had their last follow-up. The 
survival curves between the groups are signifi cantly diff erent (log 
rank P < 0.001). Data were derived from [10].
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In addition to scoring systems, levels at hospital 
admission of B-type natriuretic peptide (BNP) and the 
amino-terminal fragment of pro-BNP (NT-pro-BNP) are 
powerful predictors of outcome with regard to in-hospital 
mortality and re-hospitali zation in HF patients [25,26]. In 
open-heart surgery patients, pre operative BNP levels 
>385  pg/ml were an independent predictor of post-
operative intra-aortic balloon pump (IABP) use, hospital 
length of stay, and 1-year mortality [27]. In patients 
under going aortic valve replacement, BNP levels 
>312 pg/ml were an independent predictor of death [28]. 
Similarly, NT-pro-BNP was shown to be equivalent to 
the EuroSCORE and more accurate than preoperative left 
ventricular ejection fraction in predicting postoperative 
complications [29].
Risk modulation: cardioprotective agents
Group recommendations
• Aggressively preserving heart function during cardiac 
surgery is a major goal
• Volatile anaesthetics seem to be promising cardio-
protec tive agents
• Levosimendan, introduced more recently, also seems 
to have cardioprotective properties
• Large trials are still needed to assess the best cardio-
protective agent(s) and the optimal protocol to adopt
Besides cardioplegic and coronary perfusion optimisation 
tech niques, cardioprotective agents aim to prevent or 
diminish the extent of perioperative ischaemia-
reperfusion-induced myocardial dysfunction. Th e 
mechanisms leading to myocardial injury seem to be free 
radical formation, calcium overload, and impairment of 
the coronary vasculature [30].
Th e ultimate goal of perioperative cardioprotective 
strategies is to limit the extent and consequences of 
myocardial ischaemia-reperfusion injury. Protective 
strategies include preserving and replenishing myocardial 
high energy phos phate stores, modulating intracellular 
gradients, and the use of free radical oxygen scavengers 
and/or antioxidants, and inhibitors of the complement 
Table 1. EuroSCORE: risk factors, defi nitions and scores [16]
  Defi nition Score
Patient-related factors  
 Age Per 5 years or part thereof over 60 years 1
 Sex  Female  1
 Chronic pulmonary disease Long-term use of bronchodilators or steroids for lung disease 1
 Extracardiac arteriopathy Any one or more of the following: claudication, carotid occlusion or >50% stenosis,  2
  previous or planned intervention on the abdominal aorta, limb arteries or carotids
 Neurological dysfunction Disease severely aff ecting ambulation or day-to-day functioning 2
 Previous cardiac surgery Requiring opening of the pericardium 3
 Serum creatinine >200 μmol/l preoperatively 2
 Active endocarditis Patient still under antibiotic treatment for endocarditis at the time of surgery 3
 Critical preoperative state Any one or more of the following: ventricular tachycardia or fi brillation or aborted  3
  sudden death, preoperative cardiac massage, preoperative ventilation before arrival in 
  the anaesthetic room, preoperative inotropic support, intraaortic balloon counterpulsation 
  or preoperative acute renal failure (anuria or oliguria <10 ml/h)
Cardiac-related factors  
 Unstable angina Rest angina requiring intravenous nitrates until arrival in the anaesthetic room 2
 LV dysfunction Moderate or LVEF 30 to 50%  1
  Poor or LVEF <30  3
 Recent myocardial infarct <90 days  2
 Pulmonary hypertension Systolic PAP >60 mmHg 2
Operation-related factors  
 Emergency  Carried out on referral before the beginning of the next working day 2
 Other than isolated CABG Major cardiac procedure other than or in addition to CABG 2
 Surgery on thoracic aorta For disorder of ascending, arch or descending aorta 3
 Postinfarct septal rupture   4
Application of scoring system: 0-2 (low risk); 3-5 (medium risk); 6 plus (high risk). CABG, coronary artery bypass graft; LV, left ventricular; LVEF, left ventricular ejection 
fraction; PAP, pulmonary arterial pressure.
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systems and neutrophil activa tion. Most of these 
approaches (using adenosine modulators, cardio plegia 
solution adjuvants, Na+/H+ exchange inhibitors, KATP 
channel openers, anti-apoptotic agents, and many other 
drugs with proven or anticipated eﬀ ects on the 
complement-inﬂ ammation pathways) have been shown 
to be eﬀ ective in experimental and even observational 
clinical settings.
Clinical studies of volatile anaesthetics, which exhibit 
pharma cological preconditioning eﬀ ects, have failed to 
demonstrate unequivocally beneﬁ cial eﬀ ects with regard 
to the extent of postischaemic myocardial function and 
damage [31]. Th e use of a volatile versus intravenous 
anaesthetic regimen might be associated with better 
preserved myocardial function with less evidence of 
myo cardial damage [32-35]. Th e protective eﬀ ects seemed 
most pronounced when the volatile anaes thetic was 
applied throughout the entire surgical procedure [36]. 
Desﬂ urane and sevoﬂ urane have cardioprotective eﬀ ects 
that result in decreased morbidity and mortality 
compared to an intravenous anaesthetic regimen [37].
Postoperative morbidity and clinical recovery remains 
to be established. In a retrospective study, cardiac-related 
mortality seemed to be lower with a volatile anaesthetic 
regimen, but non-cardiac death seemed to be higher in 
this patient population, with no diﬀ erence in 30-day total 
mortality [38].
Levosimendan is increasingly described as a myocardial 
protective agent. Its anti-ischaemic eﬀ ects are mediated 
by the opening of ATP-sensitive potassium channels [39]. 
Levosimendan improves cardiac performance in 
myocardial stunning after percutaneous intervention 
[40]. Th e latest meta-analysis, including 139 patients 
from 5 randomized controlled studies, showed that 
levosimendan reduces postoperative cardiac troponin 
release irrespective of cardio pulmonary bypass (CPB; 
Figure 3). [41] Tritapepe and colleagues [12] showed that 
levosimendan pre-treatment improved outcome in 106 
patients undergoing CABG. A single dose of levo-
simendan (24 μg/kg over 10 minutes) administered before 
CPB reduced time to tracheal extubation, overall ICU 
length of stay and postoperative troponin I concentrations. 
In another recent study, levosimendan before CPB lowered 
the incidence of postoperative atrial ﬁ brillation [42]. Due 
to the complex eﬀ ects of levosimendan, and such 
preclinical and clinical results, the term inoprotector has 
been proposed to describe it [43].
Monitoring
Group recommendations
• Th e aim of monitoring is the early detection of peri-
operative cardiovascular dysfunction and assessment 
of the mechanism(s) leading to it
• Volume status is ideally assessed by ‘dynamic’ measures 
of haemodynamic parameters before and after volume 
challenge rather than single ‘static’ measures
• Heart function is ﬁ rst assessed by echocardiography 
followed by pulmonary arterial pressure, especially in 
the case of right heart dysfunction
Figure 2. Predictive probability of low cardiac output syndrome after coronary artery bypass graft. Left ventricular grade (LVGRADE) scored 
from 1 to 4. Repeat aorto-coronary bypass (ACB REDO), diabetes, age older than 70 years, left main coronary artery disease (L MAIN DISEASE), recent 
myocardial infarction (RECENT MI), and triple-vessel disease (TVD) scored 0 for no, 1 for yes. M, male; F, female; E, elective; S, semi-elective; U, urgent. 
Data were derived from [17].
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• If both volaemia and heart function are in the normal 
range, cardiovascular dysfunction is very likely related 
to vascular dysfunction
Assessing optimal volume status
Heart failure cannot be ascertained unless volume 
loading is optimal. Th e evaluation of eﬀ ective circulating 
blood volume is more important than the total blood 
volume. Signs of increased sympathetic tone and/or 
organ hypoperfusion (increased serum lactate and 
decreased mixed venous saturation (SvO2) or central 
venous O2 saturation (ScvO2)) indicate increased oxygen 
extraction secondary to altered cardiovascular physiology/ 
hypovolaemia.
It is diﬃ  cult to estimate volume status using single 
haemo dynamic measures. Pressure estimates, such as 
central venous pressure and pulmonary capillary wedge 
pressure (PCWP) - previously considered reliable 
measures of RV and LV preload - are generally insensitive 
indicators of volaemia; while low values may reﬂ ect 
hypovolaemia, high values do not necessarily indicate 
volume overload [44-47]. Th e uncoupling between 
PCWP and LV end-diastolic pressure can be the conse-
quence of elevated pulmonary vascular resistance, 
pulmonary venoconstriction, mitral stenosis and 
reductions in transmural cardiac compliance.
Volumetric estimates of preload seem more predictive 
of volume status [46]. Transoesophageal echocardio-
graphy is used clinically for assessing LV end-diastolic 
area, while the transpulmonary thermal-dye indicator 
dilution technique measures intrathoracic blood volume 
[48], which reﬂ ects both changes in volume status and 
ensuing alteration in CO, a potentially useful clinical 
indicator of overall cardiac preload [49,50].
In predicting ﬂ uid responsiveness in ICU patients, it is 
preferable to use more reliable dynamic indicators 
reﬂ ecting hypovolaemia than static parameters [51,52]. 
In particular, stroke volume variation enables real-time 
prediction and monitoring of LV response to preload 
enhancement post operatively and guides volume therapy. 
By contrast, central venous pressure and PCWP 
alterations associated with changes in circulating 
volumes do not correlate signiﬁ cantly with changes in 
end-diastolic volume and stroke volume. Th e ‘gold 
standard’ haemodynamic technique guiding volume 
management in critically ill patients is yet to be 
determined. Continuous monitoring techniques are more 
appropriate in assessing the perioperative volume status 
of HF patients.
Echocardiography
Intraoperative and postoperative transoesophageal echo-
cardio graphy (TOE) and postoperative transthoracic echo-
cardio graphy enable bedside visualization of the heart. 
Echo cardio graphy may immediately identify causes of 
cardio vascular failure, including cardiac and valvular 
dysfunction, obstruction of the RV (pulmonary embolism) 
or LV outﬂ ow tract (for example, systolic anterior motion 
of the anterior mitral valve leaﬂ et), or obstruction to 
cardiac ﬁ lling in tamponade. It might diﬀ erentiate between 
acute right, left and global HF as well as between systolic 
and diastolic dysfunction. Trans oeso phageal echo-
cardiography inﬂ uences both anaesthe tists’ and surgeons’ 
therapeutic options, especially perioperatively [53].
Pulmonary artery catheter (Swan-Ganz catheter)
After almost four decades, the pulmonary artery catheter 
(PAC) remains a monitoring method for directly measur-
ing circulatory blood ﬂ ow in critically ill patients, 
including cardio surgical patients. With regard to manag-
ing peri operative HF, the four crucial components remain 
measure ments of heart rate, volaemia, myocardial 
function and vessel tone.
In RV failure, except if caused by tamponade, a PAC 
should be introduced after an echocardiographically 
established diagnosis. PACs can diﬀ erentiate between 
pulmonary hyper tension and RV ischaemia, necessitating 
a reduction of RV afterload, as the ischaemic RV is very 
sensitive to any afterload increase [54]. Th ey are even 
more important in the worst scenario for the RV: 
combined increased pulmonary arterial pressure and RV 
ischaemia.
Table 2. Scoring systems used in cardiac surgery
  Incidence in  Mortality in 
 EF with highest risk high-risk group* high-risk group Reference
EuroSCORE <30% 3 of all, ≥6 10.25 to 12.16% [16]
Pons Score - (NYHA IV) 10 of all, ≥30 54.4% [85]
French Score ≤30% 5 of all, >6 21.2% [86]
Ontario Province Risk Score <20% 3 of all, ≥8 14.51% [87]
Cleveland Clinic Score <35% 3 of all, 10 to 31 44.6% [88]
Parsonnet Score <30% 4 of all, ≥20 >20% [89]
EF, ejection fraction; NYHA, New York Heart Association.
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Alternative measures of stroke volume
Recently, several devices have been designed to assess 
cardiac function based on pulse contour analysis of an 
arterial waveform (Table 3). Th eir value in assessing the 
failing heart’s function is still under investigation.
Pharmacological treatment of left ventricular 
dysfunction after cardiac surgery 
Group recommendations
• In case of myocardial dysfunction, consider the 
following three options either alone or combined:
• Among catecholamines, consider low-to-moderate doses 
of dobutamine and epinephrine: they both improve 
stoke volume and increase heart rate while PCWP is 
moderately decreased; catecholamines increase myo-
cardial oxygen consumption
• Milrinone decreases PCWP and SVR while increasing 
stoke volume; milrinone causes less tachycardia than 
dobutamine
• Levosimendan, a calcium sensitizer, increases stoke 
volume and heart rate and decreases SVR
• Norepinephrine should be used in case of low blood 
pressure due to vasoplegia to maintain an adequate 
perfusion pressure. Volaemia should be repeatedly 
assessed to ensure that the patient is not hypovolaemic 
while under vasopressors
• Optimal use of inotropes or vasopressors in the 
perioperative period of cardiac surgery is still 
controversial and needs further large multinational 
studies
Cardiac surgery may cause acute deterioration of 
ventricular function during and after weaning from CPB. 
Pharma co logical treatment of low CO and reduced 
oxygen delivery to vital organs may be required. 
Inadequate treatment may lead to multiple organ failure, 
one of the main causes of prolonged hospital stay, 
postoperative morbidity and mortality and, thus, 
increased health care costs. However, excess inotrope 
usage could also be associated with deleterious eﬀ ects 
through complex mechanisms [55].
A wide range of inotropic agents is available. Consensus 
regarding the pharmacological inotropic treatment for 
postcardiotomy heart failure and randomized controlled 
trials focusing on clinically important outcomes are both 
lacking. Th e vast majority of reports focus on post-
operative systemic haemodynamic eﬀ ects and, to some 
extent, on regional circulatory eﬀ ects of individual ino-
tropic agents. Furthermore, there is a shortage of 
comparative studies evaluating the diﬀ erential systemic 
and regional haemodynamic eﬀ ects of various inotropes 
on CO in postoperative HF. Catechol amines and 
phosphodiesterase inhibitors are two main groups of 
inotropes used for treatment of cardiac failure in heart 
surgery [56]. Th e calcium sensitizer levosimendan has 
recently become an interesting option for treatment of 
HF as well as in postcardiotomy ventricular dysfunction.
Catecholamines
All catecholamines have positive inotropic and chrono-
tropic eﬀ ects. In a comparison of epinephrine with 
dobutamine in patients recovering from CABG, they had 
similar eﬀ ects on mean arterial pressure, central venous 
pressure, PCWP, SVR, pulmonary vascular resistance, 
and LV stroke work [57]. Furthermore, when stoke 
volume was increased comparably, dobutamine increased 
heart rate more than epinephrine. Epinephrine, dobuta-
mine and dopamine all increase myo cardial oxygen 
consumption (MVO2) postoperatively [58-60]. However, 
only with dobutamine is this matched by a propor tional 
increase in coronary blood ﬂ ow [58,59], suggesting that 
the other agents may impair coronary vasodilatory 
reserve postoperatively. Of note, commonly encountered 
Figure 3. Cardioprotective eff ect of levosimendan in cardiac surgery. Figure taken from [41]. Data are from Barisin et al., Husedzinovic et 
al., Al-Shawaf et al. [69], Tritapepe et al. [12], and De Hert et al. [74]. CI, confi dence interval; df, degrees of freedom; SD, standard deviation; WMD, 
weighted mean diff erences.
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Table 3. Etiology and investigation of post-cardiopulmonary bypass ventricular dysfunction
Cause  Investigation Finding 
General
 Exacerbation of preoperative ventricular dysfunction with relative  TOE Global or regional wall 
 intolerance to cardioplegic asystolic, hypoxic arrest  motion abnormality
 Reperfusion injury TOE Global wall motion abnormality
 Inadequate myocardial protection (underlying coronary anatomy,  TOE Global wall motion abnormality
 route of cardioplegia, type of cardioplegia)
Case/patient specifi c
 Ischaemia/infarction  
  Vessel spasm (native coronaries, internal mammary artery) ECG, TOE, graft fl ow ECG changes, regional wall motion 
     abnormality, poor graft fl ow
  Emboli (air, clot, particulate matter) ECG, TOE, graft fl ow ECG changes, regional wall motion 
     abnormality, poor graft fl ow
  Technical graft anastomotic tissues ECG, TOE, graft fl ow ECG changes, regional wall motion 
     abnormality, poor graft fl ow
  Kink/clotting of bypass grafts, native vessels ECG, TOE, graft fl ow,  ECG changes, regional wall motion 
    inspection abnormality, poor graft fl ow
 Incomplete revascularization  
  Non-graftable vessels  
  Known intrinsic disease  
 Metabolic  
  Hypoxia, hypercarbia ABG, electrolytes, 
    check ventilation 
  Hypokalemia, hyperkalemia Electrolytes 
 Uncorrected pathology  
  Hypertrophic cardiomyopathy TOE Abnormal outfl ow gradient, SAM
  Valve gradients TOE Abnormal valve gradient
  Shunts TOE Abnormal Doppler jet
 Mechanical issues  
  Prosthetic valve function TOE Poor leafl et motion, abnormal 
     gradient
  Intracardiac shunt (ASD, VSD) TOE Abnormal Doppler jet
 Conduction issues  
  Bradycardia ECG Heart rate less than 60
  Atrioventricular dissociation ECG Third degree heart block
  Atrial fi brillation ECG, ABG, electrolytes Hypoxia, electrolyte abnormality
  Ventricular arrhythmias ECG, ABG, electrolytes Hypoxia, electrolyte abnormality
  Vasodilation Transpulmonary thermodilation,  Decreased systemic vascular 
    Swan-Ganz monitoring resistance
  Hypovolemia Stroke volume monitoring  Decreased stroke volume, 
     increased SVV
 Pulmonary hypertension  
  Pre-existing elevated pulmonary pressures, hypoxia,  ABG Elevated pulmonary artery 
  hypercarbia, fl uid overload  pressures, hypoxia, hypercarbia, 
     RV distention
 Right ventricular failure  
  Elevated pulmonary pressures, inadequate myocardial  Swan-Ganz monitoring, ABG,  RV distention, poor RV wall motion, 
  protection, emboli to native or bypass circulation, fl uid overload TOE elevated pulmonary artery pressure, 
     elevated central venous pressure
ABG = arterial blood gas; ASD, atrial septic defect; ECG, electrocardiogram, RV, right ventricle, SAM, systolic anterior motion of mitral valve leafl et; SVV, stoke volume 
variation; TOE, transoesophageal echocardiography; VSD, ventricular septal defect. Data taken from [80].
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pheno mena associated with epinephrine use include 
hyper lactateaemia and hyperglycaemia. Dopexamine has 
no haemo dynamic advantage over dopamine or dobuta-
mine [61,62] in LV dysfunction.
Phosphodiesterase III inhibitors
Phosphodiesterase III inhibitors, such as amrinone, 
milrinone or enoximone, are all potent vasodilators that 
cause reductions in cardiac ﬁ lling pressures, pulmonary 
vascular resistance and SVR [63-65]; they are commonly 
used in combination with β1-adrenergic agonists. Com-
pared to dobutamine in postoperative low CO, phos-
phodiesterase III inhibitors caused a less pronounced 
increase in heart rate and decreased the likelihood of 
arrhythmias [66-68]; also, the incidence of postoperative 
myocardial infarction was signiﬁ  cantly lower (0%) with 
amrinone compared to dobutamine (40%) [66]. Th is 
could be explained by phosphodiesterase III inhibitors 
decreasing LV wall tension without increasing MVO2, 
despite increases in heart rate and contractility, in 
striking contrast to catecholamines [59].
Levosimendan
Levosimendan has been recommended for the 
treatment of acute HF [8] and was recently used for the 
successful treatment of low CO after cardiac surgery 
[69-71]. Th e eﬀ ects of levosimendan have been 
compared to those of dobu tamine [72,73] and milrinone 
[69,74]. Levosimendan has been shown to decrease the 
time to extubation com pared to milrinone [74]. 
Compared to dobutamine, levosimen dan decreases the 
incidence of postoperative atrial ﬁ brillation [42] and 
myocardial infarction, ICU length of stay [73], acute 
renal dysfunction, ventricular arrhythmias, and 
mortality in the treatment of post operative LV 
dysfunction. Levosimendan showed little change in 
MVO2 [75] and improved early heart relaxation after 
aortic valve replacement. [76].
In summary, the above described inotropic agents can 
be started either alone or in combination with an agent 
from another class (multimodal approach) in myocardial 
depres sion. Common examples include norepinephrine 
with dobu tamine or phosphodiesterase III inhibitors, and 
dobutamine with levosimendan. Th e beneﬁ cial eﬀ ects of 
treatment with inotropic agents on outcome in the 
management of post operative low CO need to be 
conﬁ rmed in a large multicentre study.
Clinical scenarios
Group recommendations
• Th e classiﬁ cation of cardiac impairment in the peri-
operative period of cardiac surgery should be based on 
the time of occurrence:
– precardiotomy
– failure to wean
– postcardiotomy
 and on the haemodynamic severity of the condition of 
the patient:
– crash and burn
– deteriorating fast
– stable but inotrope dependent
In cardiosurgical patients the timing of surgical 
intervention in relationship to the development of acute 
HF with subsequent cardiogenic shock is of utmost 
importance, leading to three distinct clinical scenarios: 
precardiotomy HF, failure to wean and postcardiotomy 
HF. While their names are self-explana tory, these three 
distinct clinical scenarios diﬀ er from each other 
substantially concerning diagnosis, monitoring and 
management.
Th ere is consensus that cardiogenic shock is the 
severest form of HF; regardless of aetiology, patho-
physiology, or initial clinical presentation, it can be the 
ﬁ nal stage of both acute and chronic HF, with the highest 
mortality (Table 4).
Precardiotomy heart failure
In the precardiotomy HF proﬁ le the underlying pathology 
may still be obscure. Altered LV function primarily due 
to myocardial ischaemia is one of the most frequent 
causes of precardiotomy low output syndrome. Th e 
patient may be anywhere in the hospital or pre-hospital 
setting, with or without an initial working diagnosis, and 
quite often only basic monitoring options are available. 
Th e availability of life support measures may be limited 
compared with the other two scenarios. Th e primary aim 
being the patient’s survival, priorities focus on deciding 
the steps necessary for diagnosis and treatment. Th e next 
priority should be surgery avoiding further alterations in 
myocardial function, possibly by intro ducing an IABP 
preoperatively. As described above, pre operative poor LV 
function is the most important predictor of postoperative 
morbidity and mortality after CABG. However, the 
dysfunctional myocardium may not be irreversibly 
damaged and possibly only ‘stunned’ or ‘hibernating’. 
Revascularization of the reversibly injured heart areas 
may result in improved LV performance. Still cold injury 
or inhomogeneous cardioplegic delivery may exacerbate 
peri operative ischaemic injury, resulting in inadequate 
early post operative ventricular function [77]. Prolonged 
reperfusion with a terminal ‘hot shot’ of cardioplegic 
solution may restore function in patients with poor 
ventricular function [78]. Warm cardioplegia may 
improve postoperative LV function in patients with high-
risk conditions [77]. Some patients will continue to have 
poor ventricular function postoperatively, restricting the 
role of myocardial protection to limiting the extent of 
perioperative injury [79].
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Failure to wean
In the failure to wean from CPB proﬁ le, although the 
reason to perform surgery is more or less established, the 
basis for a successful therapeutic approach is establishing 
a correct diagnosis of cardiac failure as soon as possible. 
Acute HF associated with failure to wean patients oﬀ 
CPB may be surgery related, patient speciﬁ c or both, as 
summarized in Table 3 [80]. Table 3 also lists the investi-
gations necessary to ascertain the underlying cause of 
failure to wean from CPB.
Postcardiotomy heart failure
As patients with postcardiotomy HF are usually in the 
ICU, we can usually guesstimate the diagnosis. Sophis-
ticated monitoring and diagnostic and therapeutic 
options are readily available should the need arise. 
Although the chest remains closed, it can be reopened 
quickly if needed, either in the ICU bed or in theatre 
following the patient’s transfer back there. Support with 
cardiac assist devices can also be initiated, although not 
as promptly as in the failure to wean scenario. Th e 
Table 4. The three clinical heart failure scenarios and the clinical profi les in each scenario
Clinical scenarios Clinical profi les in each scenario
Precardiotomy heart failure 
 Precardiotomy crash and burn Refractory cardiogenic shock requiring emergent salvage operation: CPR en route to the
  operating theatre or prior to anaesthesia induction
  Refractory cardiogenic shock (STS defi nition SBP <80 mmHg and/or CI <1.8 L/minute/m2 
  despite maximal treatment) requiring emergency operation due to ongoing, refractory (diffi  cult, 
  complicated, and/or unmanageable) unrelenting cardiac compromise resulting in life threatening 
  haemodynamic compromise
 Precardiotomy deteriorating fast Deteriorating haemodynamic instability: increasing doses of intravenous inotropes and/or IABP 
  necessary to maintain SBP > 80mmHg and/or CI >1.8 L/minute/m2. Progressive deterioration. 
  Emergency operation required due to ongoing, refractory (diffi  cult, complicated, and/or 
  unmanageable) unrelenting cardiac compromise, resulting in severe haemodynamic compromise
 Precardiotomy stable on inotropes Inotrope dependency: intravenous inotropes and/or IABP are necessary to maintain SBP 
  >80 mmHg and/or CI >1.8 L/minute/m2 without clinical improvement. Failure to wean from 
  inotropes (decreasing inotropes results in symptomatic hypotension or organ dysfunction). 
  Urgent operation is required
Failure to wean from CPB 
 Failure to wean from CPB Cardiac arrest after prolonged weaning time (>1 hour)
 Deteriorating fast on withdrawal  Deteriorating haemodynamic instability on withdrawal of CBP after prolonged weaning time 
 from CPB (>1 hour)
  Increasing doses of intravenous inotropes and/or IABP necessary to maintain SBP >80 mmHg 
  and/or CI >1.8 L/minute/m2
 Stable but inotrope dependent on  Inotrope dependency on withdrawal of CBP after weaning time >30 minutes. Intravenous 
 withdrawal from CPB inotropes and/or IABP are necessary to maintain SBP >80 mmHg and/or CI >1.8 L/minute/m2 
  without clinical improvement 
  The high incidence of complications after VAD implantation is directly related to prolonged 
  attempted weaning periods from CPB. Application of IABP within 30 minutes from the fi rst 
  attempt to wean from CPB and mechanical circulatory support within 1 hour from the fi rst 
  attempts to wean from the CPB are suggested [90]
Postcardiotomy cardiogenic shock 
 Postcardiotomy crash and burn Cardiac arrest requiring CPR until intervention
  Refractory cardiogenic shock (SBP <80 mmHg and/or CI <1.8 L/minute/m2, critical organ 
  hypoperfusion with systemic acidosis and/or increasing lactate levels despite maximal treatment, 
  including inotropes and IABP) resulting in life threatening haemodynamic compromise. 
  Emergency salvage intervention required
 Postcardiotomy deteriorating fast Deteriorating haemodynamic instability. Increasing doses of intravenous inotropes and/or IABP 
  necessary to maintain SBP >80 mmHg and/or CI >1.8 L/minute/m2. Progressive deterioration, 
  worsening acidosis and increasing lactate levels. Emergent intervention required due to ongoing, 
  refractory unrelenting cardiac compromise, resulting in severe haemodynamic compromise
 Postcardiotomy stable on inotropes Inotrope dependency: intravenous inotropes and/or IABP necessary to maintain SBP 
  >80 mmHg and/or CI >1.8 L/minute/m2 without clinical improvement. Failure to decrease 
  inotropic support
CI, cardiac index; CPB, cardiopulmonary bypass; CPR, cardiopulmonary resuscitation; IABP, intra-aortic balloon pump; SBP, systolic blood pressure; STS, Society of 
Thoracic Surgeons; VAD, ventricular assist device.
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priority is preserving end organ function and bridging 
the patient to recovery.
Th e initial strategy for management of postcardiotomy 
cardiac dysfunction includes the optimization of both 
preload appro priate to LV function and rhythm and 
support with positive inotropic and/or vasopressor 
agents and IABP. Th is strategy will restore haemo-
dynamics in most patients. Requirements for optimal LV 
function and preservation of RV coronary perfusion 
include careful assessment of right-left ventricular inter-
actions, ventricular-aorta coupling and adequate mean 
arterial pressure. [81]
When in postcardiotomy HF an IABP becomes 
necessary, survival rates between 40% and 60% have been 
reported. In more severe cases of postcardiotomy HF, 
reported rates of hospital discharge have been dis-
appointing (6% to 44%) even with the implementation of 
extracorporeal ventricular assist devices [82].
A perioperative clinical severity classiﬁ cation of severe 
acute HF is suggested in Table 4.
Mechanical circulatory support
Group recommendations
• In case of heart dysfunction with suspected coronary 
hypoperfusion, IABP is highly recommended
• Ventricular assist device should be considered early 
rather than later, before end organ dysfunction is 
evident
• Extra-corporeal membrane oxygenation is an elegant 
solution as a bridge to recovery or decision making
Intra-aortic balloon pump
IABP is the ﬁ rst choice device in intra- and perioperative 
cardiac dysfunction. Its advantages include easy insertion 
(Seldinger technique), the modest increase in CO and 
coronary perfusion, and four decades of reﬁ ned tech-
nology and experience resulting in a low complication 
rate. Th e IABP’s main mechanism of action is a reduction 
of afterload and increased diastolic coronary perfusion 
via electro cardiogram triggered counterpulsation. However, 
the newer generations of IABPs are driven by aorta ﬂ ow 
detection, thereby overcoming limitations in patients with 
atrial ﬁ brillation and other arrhythmias. IABP reduces heart 
work and myo cardial oxygen consumption, favourably 
modifying the balance of oxygen demand/supply.
Consequently, it is an ideal application in post-
cardiotomy cardiac dysfunction, especially in suspected 
coronary hypo perfusion. IABP insertion should be 
considered as soon as evidence points to possible cardiac 
dysfunction, preferably intraoperatively to avoid the 
excessive need of inotropic support.
IABP is contraindicated for patients with severe aortic 
insuﬃ  ciency, and advanced peripheral and aortic 
vascular disease.
Catheter based axial fl ow devices
Experiences with the ﬁ rst miniaturized 14  Fr catheter 
based axial ﬂ ow pump, used in the early 1980s 
(Hemopump®), provided ﬂ ow rates in the range of 2.0 to 
2.5 L/minute, but initial mechanical problems limited its 
clinical application in supporting the failing heart.
A new design (Impella pump®) provides a more stable 
mechanical function through modiﬁ cations and improve-
ments, including both the pump-head and the 
miniaturized motor mounted on the tip of the catheter. 
However, even with these improvements transfemoral 
placement is only possible with the smallest version of this 
pump; larger diameter versions require surgical placement. 
Pump versions are available for both LV and RV support. 
Increased ﬂ ow rates in the range of 2.5 to 5.0 L/minute can 
be achieved directly in proportion with increasing 
diameter of the pumps. It is CE-marked for temporary use 
of 5 to 10 days only, and seems eﬃ  cient in medium ﬂ ow 
demands in postcardiotomy low CO syndrome.
Extra-corporeal membrane oxygenation
Extra-corporeal membrane oxygenation (ECMO) is 
increa singly used for temporary mechanical circulatory 
support due to the relatively low cost of the system and 
disposables, as well as its broad availability (practically 
accessible to all cardiosurgical units, without requiring a 
major investment in hardware). Indications include all 
types of ventricular failure, for example, intraoperative or 
perioperative low CO syn drome, severe acute myocardial 
infarction, and cardiac resusci tation. An additional 
advantage is its versatile use not only in LV, RV or 
biventricular support, but also for respiratory assistance 
and even renal support by addition of a haemoﬁ lter.
ECMO is a simpliﬁ ed CPB using a centrifugal pump (5 
to 6  L/minute), allowing for augmentation of venous 
drainage despite relatively small cannulas, with the 
option of taking the full workload over from the heart. 
ECMO is not only used as a bridge to recovery, a bridge 
to transplantation, or a bridge to assist with middle and 
long-term assist devices, but also as a bridge to decision 
making - for example, neurological assess ment after 
resuscitation prior to long-term assist/ trans plantation.
Th e limitations of ECMO mainly stem from the 
necessity of permanent operator supervision and 
intervention. Currently, many diﬀ erent ECMO conﬁ gura-
tions are available for temporary use up to 30  days. 
Although patients supported by ECMO can be extubated, 
they are usually bed-ridden and have to stay in the ICU, 
which is very much in contrast to modern ventricular 
assist device therapy (see below).
Ventricular assist device
Mechanical blood pumps, capable of taking over the full 
CO of the failing heart, are used today as an established 
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therapy option for patients with end-stage HF. In the 
majority of cases only the failing LV needs mechanical 
support; pumps are therefore left ventricular assist 
devices. Patients with pro nounced biventricular failure or 
patients in cardiogenic shock will nowadays receive 
biventricular mechanical support.
Besides achieving adequate perfusion of the peripheral 
organs, thereby facilitating survival in the ICU, 
increasingly the objective of modern ventricular assist 
device therapy is to obtain a level of functionality that 
results in an acceptable quality of life for the patient. 
Hence, weaning from the ventilator, mobilisation, 
transfer from the ICU to the general ward, excursions, 
discharge home, and ultimately return to work must be 
the goals when transplantation is not feasible within a 
reasonable time frame.
In terms of technology, the available pumps provide 
either pulsatile or continuous ﬂ ow (may be modulated by 
residual ventricular function). In continuous ﬂ ow, axial 
and centrifugal designs are distinguished. Almost all 
currently available second-generation rotary axial and 
centrifugal pumps require a transcutaneous drive line or 
cable, a serious limitation for the patient as well as a port 
of entry for infections. However, they can easily be 
miniaturized, produce no noise, have thin and ﬂ exible 
drive-lines and their driving units can be miniaturized to 
the size of a cigarette package. In third-generation rotary 
pumps the spinning rotor ﬂ oats by means of either a 
magnetic ﬁ eld or hydrodynamic levitation, never touch-
ing the pump housing, thereby eliminating mechanical 
wear. Th e second and third generation pumps have 
prospective lifetimes of more than 10 years, producing an 
acceptable quality of life.
Steadily increasing implant numbers have improved 
clinical outcomes, with 1- and 2-year survival rates of 
approximately 90% and 80%, respectively [83,84].
In summary, in this day and age mechanical circulatory 
support should be considered as a course of treatment 
and not as a last eﬀ ort in patients with failing hearts, 
especially those with perioperative cardiac dysfunction 
inadequately responding to advanced inotropic treat-
ment. Initially, most patients demonstrating peri-
operative low CO syndrome receive short-term mecha-
nical support. Under this initial support they stabilize or 
recover and can be weaned from the pump (bridge to 
recovery). Patients, whose cardiac function does not 
recover during the initial support and are eligible for 
cardiac transplantation can be switched to long-term 
mecha nical support (bridge to transplantation, chronic 
mechanical support as an alternative to transplantation). 
If the haemo dynamics are inadequate with an unclear 
indication for potentially long-term assist, ECMO 
provides an elegant low cost and short-term solution as a 
bridge to recovery. Table  5 summarizes short- and 
long-term mechanical circulatory devices used in the 
three clinical scenarios.
Conclusion
Th is review oﬀ ers practical recommendations for 
managing perioperative HF in cardiac surgery based 
mostly on European experts’ opinion. It outlines typical 
scenarios and proﬁ les classifying and deﬁ ning low CO 
syndrome and cardiogenic shock in cardiac surgery. As 
the role of inotropes is accentuated, the cardiosurgical 
community needs to have evidence-based facts on the 
short- and long-term mortality in cardiac surgery in 
European cardiosurgical centres. Th e impact of inotropes 
is increasingly studied outside of cardiac surgery, 
highlighting the urgent necessity for cardiac surgery to 
mimic these studies. Similarly, large trials are still 
required to assess the best cardioprotective agent(s) and 
optimal protocol(s) for their use. Th e continuously 
expanding implementation of mechanical circulatory 
support - by means of short-term (extra- or para-
corporeal) and long-term (implantable) devices - demand 
its documentation and study in a European registry.
Table 5. Mechanical circulatory support used in the three 
clinical heart failure scenarios
Clinical scenarios Commonly used devices
Precardiotomy HF IABP
 Micro-axial fl ow pumpa
 Percutaneous (transfemoral) ECMO
 LA femoral artery centrifugal pumpb
Failure to wean from CPB IABP
 Micro-axial fl ow pumpa
 ECMO
 Centrifugal pumps as LVAD, RVAD, 
 BVAD
 Percutaneous pulsatile devices as 
 LVAD, RVAD, BVADc
 Long-term implantable devices
Postcardiotomy HF IABP
 Micro-axial fl ow pump
 ECMO
 Centrifugal pumpsd as LVAD, RVAD, 
 BVAD
 Percutaneous pulsatile devicesc as 
 LVAD, RVAD, BVAD
 Long-term implantable devices fi rst, 
 second and third generation
aImpella; bTandemHeart; cAbiomed BVS 5000, AB 5000; Thoratec PVAD, Berlin 
Heart EXCOR; dCentrimag Levitronix, Biomedicus Medtronic etc. ll devices except 
those specifi ed as long term are for short-term support. BVAD, bi-ventricular 
assist device; CPB, cardiopulmonary bypass; ECMO, extracorporeal membrane 
oxygenation; HF, heart failure; IABP, intra-aortic balloon pump; LA, left atrial; 
LVAD, left ventricular assist device; PVAD, paracorporeal ventricular assist device; 
RVAD, right ventricular assist device.
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